These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Hauge M; Vestmar MA; Husted AS; Ekberg JP; Wright MJ; Di Salvo J; Weinglass AB; Engelstoft MS; Madsen AN; Lückmann M; Miller MW; Trujillo ME; Frimurer TM; Holst B; Howard AD; Schwartz TW Mol Metab; 2015 Jan; 4(1):3-14. PubMed ID: 25685685 [TBL] [Abstract][Full Text] [Related]
29. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models. Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688 [TBL] [Abstract][Full Text] [Related]
30. Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. Christiansen E; Due-Hansen ME; Urban C; Merten N; Pfleiderer M; Karlsen KK; Rasmussen SS; Steensgaard M; Hamacher A; Schmidt J; Drewke C; Petersen RK; Kristiansen K; Ullrich S; Kostenis E; Kassack MU; Ulven T ACS Med Chem Lett; 2010 Oct; 1(7):345-9. PubMed ID: 24900217 [TBL] [Abstract][Full Text] [Related]
31. Point mutation of Ffar1 abrogates fatty acid-dependent insulin secretion, but protects against HFD-induced glucose intolerance. Sabrautzki S; Kaiser G; Przemeck GKH; Gerst F; Lorza-Gil E; Panse M; Sartorius T; Hoene M; Marschall S; Häring HU; Hrabě de Angelis M; Ullrich S Mol Metab; 2017 Oct; 6(10):1304-1312. PubMed ID: 29031729 [TBL] [Abstract][Full Text] [Related]
32. AMG 837: a potent, orally bioavailable GPR40 agonist. Houze JB; Zhu L; Sun Y; Akerman M; Qiu W; Zhang AJ; Sharma R; Schmitt M; Wang Y; Liu J; Liu J; Medina JC; Reagan JD; Luo J; Tonn G; Zhang J; Lu JY; Chen M; Lopez E; Nguyen K; Yang L; Tang L; Tian H; Shuttleworth SJ; Lin DC Bioorg Med Chem Lett; 2012 Jan; 22(2):1267-70. PubMed ID: 22217876 [TBL] [Abstract][Full Text] [Related]
33. Screening of a novel free fatty acid receptor 1 (FFAR1) agonist peptide by phage display and machine learning based-amino acid substitution. Yoshioka K; Yamashita H; Shimizu K; Shimomura S; Shibata T; Miyazaki JI; Honda H Biochem Biophys Res Commun; 2021 Apr; 550():177-183. PubMed ID: 33706101 [TBL] [Abstract][Full Text] [Related]
34. Structure-Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists. Zhao X; Yoon DO; Yoo J; Park HJ J Med Chem; 2021 Apr; 64(7):4130-4149. PubMed ID: 33769827 [TBL] [Abstract][Full Text] [Related]
35. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176 [TBL] [Abstract][Full Text] [Related]
36. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes. Chen Y; Song M; Riley JP; Hu CC; Peng X; Scheuner D; Bokvist K; Maiti P; Kahl SD; Montrose-Rafizadeh C; Hamdouchi C; Miller AR Pharmacol Res Perspect; 2016 Dec; 4(6):e00278. PubMed ID: 28097011 [TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751 [TBL] [Abstract][Full Text] [Related]